KIR3DL2
Killer cell immunoglobulin-like receptor 3DL2
As of the edition of 20 October 2026, KIR3DL2 (killer cell immunoglobulin-like receptor 3DL2, UniProt P43630) has 1 drug tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P43630
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Blood and lymph; Cancer; Immune system
- Registered trials of its drugs
- 4
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lacutamab | Active | Phase 2 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Engaged | 1 |
| Total on the list | 1 |